Screening models for ADC development

Annual World of ADC 2025 -- Antibody-drug conjugates (ADCs) represent a groundbreaking advancement in the cancer treatment landscape. These therapeutic agents combine the specific binding capacity of a monoclonal antibody with a cytotoxic payload that can kill both target and bystander cells. A key consideration in defining an appropriate breast cancer treatment regimen is the expression level of human epidermal growth factor receptor 2 (HER-2), which can be targeted using the antibody Trastuzumab.